Skip to main content
OpenTrials
Completed

NCT Number: NCT07123337

Serum 25-Hydroxyvitamin D and Neurological Disability in Multiple Sclerosis

Vitamin D is hypothesized to play a role in the immunopathology and progression of multiple sclerosis (MS), yet its association with neurological disability remains uncertain, particularly in North African populations.We conducted a cross-sectional study involving 369 adult MS patients across two tertiary neurology centers in Western Libya. Serum 25-hydroxyvitamin D [25(OH)D] levels and Expanded Disability Status Scale (EDSS) scores were collected. Pearson correlation, ANOVA, and multivariable linear regression were used to assess associations between vitamin D and disability, adjusting for age, BMI, disease duration, and physical activity. Missing data and outliers were handled systematically using validated R and Python workflows.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Multiple Sclerosis Autoimmune Diseases Autoimmune Diseases of the Nervous System Demyelinating Autoimmune Diseases, CNS Demyelinating Diseases Immune System Diseases Nervous System Diseases

Age range

18 year–70 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Faculty of medicine zintan university

Tripoli, 218, Libya

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Libyan nationals.
  • aged 18 years or older.
  • diagnosis of MS based on the 2017 revised McDonald criteria.
  • capable of providing informed consent.
  • had complete clinical, demographic, and biochemical data.

Exclusion criteria

  • presence of other neurological disorders that could mimic MS (e.g., neuromyelitis optica spectrum disorder or Lyme disease).
  • missing or incomplete medical records.
  • pregnancy or lactation.
  • extreme psychiatric or cognitive impairment.

Treatment and study plan

Primary outcomes

  1. EDSS

    Time frame: 24 months

    interaction between levels of Vit D and EDSS

  2. Serum 25-Hydroxyvitamin D

    Time frame: 24 months

    levels of Vit D

Sponsors and collaborators

Lead sponsor

University of Zintan

Other

Registry information

Official study title

Serum 25-Hydroxyvitamin D and Neurological Disability in Multiple Sclerosis: A Cross-Sectional Study From the Mediterranean Epidemiological Frontier

Acronym: EDSS

Important dates

Study start
2023
Primary completion
2025
Study completion
2025
First posted
Aug 14, 2025
Registry last updated
Aug 19, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.